Properties (61)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:acquisition |
Acquired_by_Sun_Pharmaceutical_Industries_in_2014
|
gptkbp:awards |
Various industry awards
|
gptkbp:CEO |
Abhay_Gandhi
|
gptkbp:certifications |
ISO_certified
|
gptkbp:challenges |
Technological advancements
Intellectual property issues Supply chain disruptions Consumer preferences Market competition Regulatory challenges Quality control issues Global economic conditions Product recalls Supply chain issues Labor issues Healthcare reforms Changing regulations Public perception issues Technological disruptions Currency fluctuations Pricing pressures Market access barriers Emerging market dynamics Patent litigations Trade_policies Healthcare_costs |
gptkbp:clinicalTrials |
Conducts clinical trials
|
gptkbp:communityEngagement |
Health awareness campaigns
|
gptkbp:employees |
Approximately 1,000
|
gptkbp:focus |
Research and development
|
gptkbp:founded |
1994
|
gptkbp:headquarters |
gptkb:Princeton,_New_Jersey
|
https://www.w3.org/2000/01/rdf-schema#label |
Ranbaxy USA Inc.
|
gptkbp:industry |
Pharmaceuticals
|
gptkbp:keyPeople |
gptkb:Dilip_Shanghvi
|
gptkbp:location |
gptkb:North_America
|
gptkbp:market |
gptkb:United_States
|
gptkbp:parentCompany |
gptkb:Sun_Pharmaceutical_Industries
|
gptkbp:partnerships |
Various healthcare organizations
|
gptkbp:productLine |
Antibiotics
Vaccines Oncology drugs Dermatology products Nutraceuticals Cardiovascular drugs Diabetes medications Pain management drugs CNS drugs Gastrointestinal drugs Respiratory drugs Hormonal drugs |
gptkbp:products |
Generic_drugs
|
gptkbp:regulatoryCompliance |
FDA_approved_products
|
gptkbp:researchInterest |
Multiple_locations_in_the_USA
|
gptkbp:revenue |
$1 billion (approx.)
|
gptkbp:services |
Pharmaceutical manufacturing
|
gptkbp:subsidiary |
gptkb:Ranbaxy_Laboratories_Limited
|
gptkbp:sustainabilityInitiatives |
Environmental responsibility programs
|
gptkbp:type |
Public company
|
gptkbp:website |
www.ranbaxy.com
|